| pubmed-article:11734231 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11734231 | lifeskim:mentions | umls-concept:C0023977 | lld:lifeskim |
| pubmed-article:11734231 | lifeskim:mentions | umls-concept:C0001206 | lld:lifeskim |
| pubmed-article:11734231 | lifeskim:mentions | umls-concept:C0913469 | lld:lifeskim |
| pubmed-article:11734231 | lifeskim:mentions | umls-concept:C1947982 | lld:lifeskim |
| pubmed-article:11734231 | pubmed:issue | 9295 | lld:pubmed |
| pubmed-article:11734231 | pubmed:dateCreated | 2001-12-5 | lld:pubmed |
| pubmed-article:11734231 | pubmed:abstractText | Pegvisomant is a new growth hormone receptor antagonist that improves symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients with acromegaly treated for up to 12 weeks. We assessed the effects of pegvisomant in 160 patients with acromegaly treated for an average of 425 days. | lld:pubmed |
| pubmed-article:11734231 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11734231 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11734231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11734231 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11734231 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11734231 | pubmed:issn | 0140-6736 | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:BesserG MGM | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:ThornerM OMO | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:PhillipsL SLS | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:MelmedSS | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:CookD MDM | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:ClemmonsD RDR | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:ScarlettJ AJA | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:StewartP MPM | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:FriendK EKE | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:DavisR JRJ | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:BarlowC FCF | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:VanceM LML | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:KlibanskiAA | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:TrainerP JPJ | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:KatznelsonLL | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:JohannssonGG | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:StrasburgerC... | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:HackettSS | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:ZhuK MKM | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:StavrouSS | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:Herman-Bonert... | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:FredaP UPU | lld:pubmed |
| pubmed-article:11734231 | pubmed:author | pubmed-author:HutsonR KRK | lld:pubmed |
| pubmed-article:11734231 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11734231 | pubmed:day | 24 | lld:pubmed |
| pubmed-article:11734231 | pubmed:volume | 358 | lld:pubmed |
| pubmed-article:11734231 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11734231 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11734231 | pubmed:pagination | 1754-9 | lld:pubmed |
| pubmed-article:11734231 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:meshHeading | pubmed-meshheading:11734231... | lld:pubmed |
| pubmed-article:11734231 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11734231 | pubmed:articleTitle | Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. | lld:pubmed |
| pubmed-article:11734231 | pubmed:affiliation | Erasmus Medical Centre Rotterdam, 40 Dr Molewaterplein, 3015 GD, Rotterdam, Netherlands. vanderlely@inw3.azr.nl | lld:pubmed |
| pubmed-article:11734231 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11734231 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11734231 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11734231 | lld:pubmed |
